Delivery Order SPE2DB20D2104-SPE2DB24FR64U
- Not listed
- The U.S. government agency, the Defense Logistics Agency (DLA), awarded a Delivery Order contract valued at $2,944.99 to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of the pharmaceutical product XIFAXAN 550 MG TABLET 60S, with a completion date of December 11, 2023. This contract is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award, valued at $79,357.76, is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for...
- This federal contract award, valued at $38,715.97, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of March 1, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, at a ceiling value of $48,281.46. The contract has an ultimate completion date of November 20, 2023 and was awarded on November 17, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up...
- This federal contract award, valued at $16,368.85, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, to support military healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026....
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $37,028.62, is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. This is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which has a ceiling value of $999,999,999.00 and runs through November 2026. The contract does...
- This federal contract award, issued by the Defense Logistics Agency (DLA) Troop Support Medical, is a Delivery Order valued at $42,891.12 for the pharmaceutical product XIFAXAN 550 MG TABLET 60S. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026....
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of XIFAXAN 550 MG TABLET 60S. The award, valued at $1,398.21, is a firm fixed-price contract with an ultimate completion date of January 18, 2022. This order is placed under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. The IDC...
- This federal contract award is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, to the Defense Logistics Agency (DLA) by the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has a ceiling value of $5,836.21 and was awarded on December 13, 2021 with a completion date of December 14, 2021. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued...
- This federal contract award, valued at $1,316.79, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a performance period ending on March 11, 2024. This is a firm-fixed-price delivery order contract, and there is no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB24FR64UDelivery Order
This federal contract award, valued at $12,574.87, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a completion date of December 15, 2023. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 31, 2025. The IDC enables the DLA to efficiently procure a wide range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other critical healthcare commodities, to support military and veteran healthcare programs globally. The contract award did not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.6k | 12/14/23 |